Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Recurrent Gene Mutations and Clinical Outcome in the Context of Lenalidomide Treatment of Relapsed/Refractory CLL — Results from Multicenter Phase II Trial CLL-009

Veronika Opatrna, MD, Eugen Tausch, MD, Graeme Fraser, MD, Anne-Sophie Michallet, MD PhD, Peter Hillmen, MBChB, PhD, Jan Dürig, MD, Matt Kalaycio, MD, John G. Gribben, MDDSc FMedSci, Thomas J. Kipps, MD, Brendan Purse, Jennie Zhang, Sabine De Bedout, Asher A. Chanan-Khan, MD, Michael J. Hallek, MD, Clemens-Martin Wendtner, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD PhD

Blood (2017) 130 (Supplement 1): 4311.

https://doi.org/10.1182/blood.V130.Suppl_1.4311.4311

Published: 2017

Journal Articles

Initial Results of Ibrutinib Plus Venetoclax in Relapsed, Refractory CLL (Bloodwise TAP CLARITY Study): High Rates of Overall Response, Complete Remission and MRD Eradication after 6 Months of Combination Therapy

Peter Hillmen, MBChB, PhD, Talha Munir, Andy Rawstron, PhD, Kristian Brock, MSc, BSc, Samuel Munoz Vicente, MSc, Francesca Yates, PhD, Rebecca Bishop, BSc, Christopher Fegan, MD, Donald Macdonald, Alison McCaig, PhD, Anna Schuh, MD PhD, Andrew Pettitt, FRCPath, PhD, John G. Gribben, MDDSc FMedSci, Stephen Devereux, FRCP, FRCPath, PhD, Adrian Bloor, Christopher P Fox, MBChB PhD, Francesco Forconi, MD DM, PhD FRCPath

Blood (2017) 130 (Supplement 1): 428.

https://doi.org/10.1182/blood.V130.Suppl_1.428.428

Published: 2017

Journal Articles

An Integrated Safety Analysis of the Next Generation PI3Kδ Inhibitor Umbralisib (TGR-1202) in Patients with Relapsed/Refractory Lymphoid Malignancies

Blood (2017) 130 (Supplement 1): 4037.

https://doi.org/10.1182/blood.V130.Suppl_1.4037.4037

Published: 2017

Journal Articles

Increased Levels of Soluble RAGE in CLL Patient Plasma Has a Protective Effect on CLL Disease Progression

Faith Norster, Robert Petty, PhD, John G. Gribben, MDDSc FMedSci, Li Jia, MD PhD

Blood (2017) 130 (Supplement 1): 4292.

https://doi.org/10.1182/blood.V130.Suppl_1.4292.4292

Published: 2017

Journal Articles

Human Gastro-Intestinal Graft-Versus-Host Disease Is Mediated By Retinoic Acid-Responsive CD8 + Effector T-Cells Under IL-23 Polarising Conditions

Jennifer A Ball, PhD, Andrew James Clear, BSc, Maria Calaminici, MD PhD, Andrew Stagg, BSc (Hons), PhD, James Lindsay, FRCP PhDBM BCh, John G. Gribben, MDDSc FMedSci, Jeff Davies, MBBS, PhD

Blood (2017) 130 (Supplement 1): 77.

https://doi.org/10.1182/blood.V130.Suppl_1.77.77

Published: 2017

Journal Articles

Genomic Profiling Reveals Spatial Intra-Tumor Heterogeneity in Follicular Lymphoma

Blood (2017) 130 (Supplement 1): 2730.

https://doi.org/10.1182/blood.V130.Suppl_1.2730.2730

Published: 2017

Journal Articles

Longitudinal Analyses of the Genomic, Transcriptomic, and T Cell Repertoire in Diffuse Large B Cell Lymphoma Demonstrates Changes in Signaling and Immune Recognition at Relapse

Blood (2017) 130 (Supplement 1): 2734.

https://doi.org/10.1182/blood.V130.Suppl_1.2734.2734

Published: 2017

Journal Articles

High-Resolution SNP-Array Profiling of "Ultra-High Risk" CLL Cases Reveals New Recurrent Genomic Alterations

Jennifer Edelmann, MD PhD, Karlheinz Holzmann, Dr. rer. nat., Eugen Tausch, MD, Anna Dolnik, PhD, Tamara J. Blätte, MSc, Stefan Ibach, Dr, Jenny Saub, Daniel Mertens, PhD, Lars Bullinger, MD, Kirsten Fischer, MD, Valentin Goede, MD, John G. Gribben, MDDSc FMedSci, Michael J. Hallek, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD PhD

Blood (2017) 130 (Supplement 1): 2992.

https://doi.org/10.1182/blood.V130.Suppl_1.2992.2992

Published: 2017

Journal Articles

First in Human, Phase I/II Trial of the Bruton's Tyrosine Kinase Inhibitor (BTKi) M7583 in Patients with B Cell Malignancies: Study Design and Initial Outcomes

Wojciech Jurczak, Simon Rule, MD, William Townsend, David Tucker, Martin Dyroff, Barbara Sarholz, Jürgen Scheele, John G. Gribben, MDDSc FMedSci, Pier Luigi Zinzani, MD

Blood (2017) 130 (Supplement 1): 2778.

https://doi.org/10.1182/blood.V130.Suppl_1.2778.2778

Published: 2017

Journal Articles

Response to the EZH2 Inhibitor Tazemetostat Is Independent of Cell of Origin Determined Via Hans Imunohistochemistry or Nanostring Lymphoma Subtyping Test in EZH2 Wild-Type DLBCL Patients

Blood (2017) 130 (Supplement 1): 2745.

https://doi.org/10.1182/blood.V130.Suppl_1.2745.2745

Published: 2017

Journal Articles

Rituximab Activates NOTCH1 Signaling in CLL Cells and Induces Changes in the Cytokine Repertoire Favoring a Tumor-Protective Microenvironment

Jennifer Edelmann, MD PhD, Karlheinz Holzmann, Dr. rer. nat., Doriana DiBella, Emma Vilventhraraja, Stephen A Beers, PhD, Mark Cragg, PhD, Andrejs Braun, PhD, John G. Gribben, MDDSc FMedSci

Blood (2017) 130 (Supplement 1): 2996.

https://doi.org/10.1182/blood.V130.Suppl_1.2996.2996

Published: 2017

Journal Articles

Adipocyte Induced Antagonism of ALL Growth Highlights a Novel Inhibitory Niche and Potential Therapeutic Opportunity

Nicholas Warrick, BSc, Farideh Miraki-Moud, PhD, A Aicher, Linda Ariza McNaughton, Pedro Casado-Izquierdo, Ai Nagano, PhD, Rebecca Carroll, Dominique Bonnet, PhD, John G. Gribben, MDDSc FMedSci, Bela Patel, MD

Blood (2017) 130 (Supplement 1): 371.

https://doi.org/10.1182/blood.V130.Suppl_1.371.371

Published: 2017

Journal Articles

Integrative Analysis of 1001 Diffuse Large B Cell Lymphoma Identifies Novel Oncogenic Roles for Rhoa

Jenny Zhang, BSc, Anupama Reddy, PhD, Nicholas Davis, BSc, Andrea Moffitt, PhD, Cassandra Love, Alexander Waldrop, PhD, Sirpa Leppa, MD, Annika Pasanen, MD, Leo Meriranta, MS, Marja-Liisa Karjalainen-Lindsberg, Peter H. Norgaard, MDPhD, Mette Ø Pedersen, MD, Anne Ortved Gang, Estrid Hogdall, PhD, Tayla Heavican, Waseem Lone, PhD, Javeed Iqbal, MSc, PhD, Guojie Li, PhD, So Young Kim, PhD, Jane Healy, MD PhD, Kristy L. Richards, MD PhD, Yuri Fedoriw, MD, Leon Bernal-Mizrachi, MD, Jean L. Koff, MD, Ashley D. Staton, MD, Christopher Flowers, MD, Ora Paltiel-Clarfield, Neta Goldschmidt, MD, Maria Calaminici, MD PhD, Andrew James Clear, BSc, John G. Gribben, MDDSc FMedSci, Evelyn Nguyen, Magdalena Czader, MD PhD, Sarah L. Ondrejka, MD, Angela Collie, MD PhD, Eric D. Hsi, MD, Eric Tse, MBBS, PhD FRCP, FRCPath, Rex Au-Yeung, Yok-Lam Kwong, Gopesh Srivastava, William Choi, MBBS,MRCP, Andrew M Evens, DO,MSc, Monika Pilichowska, MD PhD, Manju Sengar, MD DM, Nishitha Reddy, MD MSCI, MBBS, Shaoying Li, MD, Amy Chadburn, MD, Leo I. Gordon, MD, Elaine S. Jaffe, MD, Rachel Rempel, Tiffany Tzeng, Tushar Dave, Lanie Happ, Deepthi Rajagopalan, Jyotishka Datta, David Dunson, Sandeep Dave, MD

Blood (2017) 130 (Supplement 1): 37.

https://doi.org/10.1182/blood.V130.Suppl_1.37.37

Published: 2017

Journal Articles

Sustained Reduction of Intracellular Calcium Is Important to Maximise GA101-Mediated Direct Cell Death in B-Cell Lymphomas

Emma Vilventhraraja, Jennifer Edelmann, MD PhD, Faith Norster, Andrejs Braun, PhD, John G. Gribben, MDDSc FMedSci, Pedro Cutillas, PhD, Arran Dokal, MSc

Blood (2017) 130 (Supplement 1): 1269.

https://doi.org/10.1182/blood.V130.Suppl_1.1269.1269

Published: 2017

Journal Articles

Safety, Efficacy and MRD Negativity of a Combination of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia - Results from a Phase 1b Study (GP28331)

Ian W. Flinn, MD PhD, John G. Gribben, MDDSc FMedSci, Martin J.S. Dyer, William G Wierda, MD PhD, Michael B. Maris, Richard R. Furman, MD, Peter Hillmen, MBChB, PhD, Jeffrey Jones, MD, Swami P. Iyer, MD, Surai Jones, Yanwen Jiang, Daniela Soriano Pignataro, Kathryn Humphrey, Mehrdad Mobasher, Thomas J. Kipps, MD

Blood (2017) 130 (Supplement 1): 430.

https://doi.org/10.1182/blood.V130.Suppl_1.430.430

Published: 2017

Journal Articles

The Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: An Analysis By the EBMT Complications and Quality of Life WP

Blood (2017) 130 (Supplement 1): 3324.

https://doi.org/10.1182/blood.V130.Suppl_1.3324.3324

Published: 2017

NARROW

Recurrent Gene Mutations and Clinical Outcome in the Context of Lenalidomide Treatment of Relapsed/Refractory CLL — Results from Multicenter Phase II Trial CLL-009

Initial Results of Ibrutinib Plus Venetoclax in Relapsed, Refractory CLL (Bloodwise TAP CLARITY Study): High Rates of Overall Response, Complete Remission and MRD Eradication after 6 Months of Combination Therapy

An Integrated Safety Analysis of the Next Generation PI3Kδ Inhibitor Umbralisib (TGR-1202) in Patients with Relapsed/Refractory Lymphoid Malignancies

Increased Levels of Soluble RAGE in CLL Patient Plasma Has a Protective Effect on CLL Disease Progression

Human Gastro-Intestinal Graft-Versus-Host Disease Is Mediated By Retinoic Acid-Responsive CD8 + Effector T-Cells Under IL-23 Polarising Conditions

Genomic Profiling Reveals Spatial Intra-Tumor Heterogeneity in Follicular Lymphoma

Longitudinal Analyses of the Genomic, Transcriptomic, and T Cell Repertoire in Diffuse Large B Cell Lymphoma Demonstrates Changes in Signaling and Immune Recognition at Relapse

High-Resolution SNP-Array Profiling of "Ultra-High Risk" CLL Cases Reveals New Recurrent Genomic Alterations

First in Human, Phase I/II Trial of the Bruton's Tyrosine Kinase Inhibitor (BTKi) M7583 in Patients with B Cell Malignancies: Study Design and Initial Outcomes

Response to the EZH2 Inhibitor Tazemetostat Is Independent of Cell of Origin Determined Via Hans Imunohistochemistry or Nanostring Lymphoma Subtyping Test in EZH2 Wild-Type DLBCL Patients

Rituximab Activates NOTCH1 Signaling in CLL Cells and Induces Changes in the Cytokine Repertoire Favoring a Tumor-Protective Microenvironment

Adipocyte Induced Antagonism of ALL Growth Highlights a Novel Inhibitory Niche and Potential Therapeutic Opportunity

Integrative Analysis of 1001 Diffuse Large B Cell Lymphoma Identifies Novel Oncogenic Roles for Rhoa

Sustained Reduction of Intracellular Calcium Is Important to Maximise GA101-Mediated Direct Cell Death in B-Cell Lymphomas

Safety, Efficacy and MRD Negativity of a Combination of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia - Results from a Phase 1b Study (GP28331)

The Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: An Analysis By the EBMT Complications and Quality of Life WP

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only